Search research articles
Contact Us
Filters
Showing results (211-220 of 430) with videos related to
Page
of 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy
Sara S Strom, Xuemei Wang, Curtis A Pettaway, et al.
Oncogene
|
December 3, 2003
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells
Kevin B Spurgers, Kevin R Coombes, Raymond E Meyn, et al.
The Journal of Urology
|
February 26, 1999
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential
N M Navone, M E Labate, P Troncoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer
Eleni Efstathiou, Patricia Troncoso, Sijin Wen, et al.
The Prostate
|
March 30, 2012
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b
Maria Karlou, Jing-Fang Lu, Guanglin Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
Christos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 29, 2021
Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<b>β</b>1 Integrin Targeting
Claudia Paindelli, Stefano Casarin, Feng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer
Randall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Carcinogenesis
|
August 13, 2016
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance
Xiang Shu, Yuanqing Ye, Jian Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
Arlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.
Page
of 43
Search research articles
Search
Showing results (211-220 of 430) with videos related to
Sort By:
Page
of 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy
Sara S Strom, Xuemei Wang, Curtis A Pettaway, et al.
Oncogene
|
December 3, 2003
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells
Kevin B Spurgers, Kevin R Coombes, Raymond E Meyn, et al.
The Journal of Urology
|
February 26, 1999
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential
N M Navone, M E Labate, P Troncoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer
Eleni Efstathiou, Patricia Troncoso, Sijin Wen, et al.
The Prostate
|
March 30, 2012
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b
Maria Karlou, Jing-Fang Lu, Guanglin Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
Christos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 29, 2021
Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<b>β</b>1 Integrin Targeting
Claudia Paindelli, Stefano Casarin, Feng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer
Randall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Carcinogenesis
|
August 13, 2016
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance
Xiang Shu, Yuanqing Ye, Jian Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
Arlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.
Page
of 43